Genentech Alteplase In Line For August Action On Catheter Clearance sBLA
This article was originally published in Pharmaceutical Approvals Monthly
Genentech’s Activase (alteplase) sBLA for unclogging central venous access catheters (CVAC) is based on study results showing a 74% rate of clearance following the first dose of the recombinant tissue plasminogen activator (t-PA).
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class